UK firm Biocompatibles International says that sales of PC(phosphorylcholine) technology products and its cardiovascular and eye-care divisions in the first two months of 2001, were well ahead of the like, 2000 period, although Hydron eye-care products remained static.
In the cardiovascular division, first-half 2001 turnover of the firm's BiodivYsio line of PC technology stent products were around 43% higher, with strong sales growth seen in the UK, Germany, Latin America and Asia. In the drug delivery division, recruitment was completed in a trial for the dexamethasone-loaded stent (STRIDE), and the trial of a stent delivering British Biotech's batimastat (BRILLIANT) is expected to start shortly.
First-half sales of the eye-care division were around 17% ahead of 2000 on a like-for-like basis, with turnover of the Proclear line of PC technology products up 38%. The strongest areas of growth were the countries where the acquisition of Hydron provided new direct sales forces, notably in the Netherlands, Italy, Spain, France, Australia and South Africa.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze